Business Context and Reporting Period
This Form 8-K is a current report filed by Signal Genetics, Inc. (not Viridian Therapeutics, Inc.) on August 12, 2015. The filing serves to disclose a business update and financial results for the second quarter of 2015 via a press release incorporated by reference as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the attached press release (Exhibit 99.1), which is not included in the source text.
Material Changes
The filing indicates the company is reporting "Recent Achievements" and "Second Quarter 2015 Financial Results." However, the specific nature of these achievements and the quantitative changes compared to prior periods are not detailed in the provided text.
Guidance, Outlook, and Risks
The document incorporates a press release regarding a business update but does not explicitly state forward-looking guidance, management commentary, specific risks, or contingencies within the text provided. The filing includes a standard disclaimer that the information is not deemed filed for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Verify the specific Q2 2015 financial figures (revenue, net loss, cash position) in the attached Exhibit 99.1 press release.
- Confirm the details of the "Recent Achievements" mentioned in the business update.
- Review the full press release for any updated operational guidance or risk factors not summarized in the 8-K header.
- Note the discrepancy between the requested company name (Viridian Therapeutics) and the actual registrant (Signal Genetics, Inc.).